Protein engineering, production, reconstitution in lipid nanoparticles, and initial characterization of the *Mycobacterium tuberculosis* EfpA drug exporter

Olamide Ishola[1], Adeyemi Ogunbowale[1], Md Majharul Islam[1], Elaheh Hadadianpour[1], Saman Majeed[1], Oluwatosin Adetuyi[1], Elka R. Georgieva[1,2]*

[1]Department of Chemistry and Biochemistry, Texas Tech University, Lubbock, TX 79409

[2]Center for Membrane Protein Research, TTU Health Science Center, Lubbock, TX 79430, USA

*Correspondence: Elka R. Georgieva, Department of Chemistry and Biochemistry, Texas Tech University, e-mail: elgeorgi@ttu.edu

ABSTRACT

Mycobacterium tuberculosis (*Mtb*) drug exporters contribute an efficient mechanism for drug resistance. Therefore, understanding the structure–function relationship in these proteins is important. We focused on the *Mtb* EfpA efflux pump, which belongs to the major facilitator superfamily (MSF) and transports anti-tuberculosis drugs outside the bacterial cell. Here, we report on our advancements in producing and *in vitro* characterization of this protein. We engineered a construct of apolipoprotein AI (apoAI) fused to the N-terminus of EfpA (apoAI-EfpA) and cloned it in an *E. coli* expression vector. This fusion construct was found in a membrane-bound form, unlike the deposited in inclusion bodies EfpA without apoAI. We purified the apoAI-EfpA in detergent to a sufficient degree and reconstituted it in DOPC/DOPS lipids. We found that upon reconstitution in lipid, the apoAI-EfpA forms discoidal protein-lipid nanostructures with a diameter of about 20 nm, resembling nanodiscs. We further detected apoAI-EfpA form oligomers in β-DDM and lipid. To the best of our knowledge, this is the first complete protocol on the expression, purification, and lipid reconstitution of the *Mtb* EfpA reported. Our bioinformatic analysis confirmed the earlier proposed 14-transmembrane helices of the *Mtb* EfpA. We also found very high identity, >80%, among the EfpAss of diverse *mycobacterial* species. Outside of *mycobacteria*, EfpA has no close homologues with only low identity with the QacA family of transporters. These findings possibly indicate high specificity of EfpA mechanisms. Our developments provide a foundation for more comprehensive in vitro studies on the EfpA exporter.

IMPORTANCE

Mycobacterium tuberculosis (*Mtb*) is a highly contagious and resilient pathogenic bacterium that in infected individuals leads to the very serious disease tuberculosis (TB). *Mtb* often acquires drug and multidrug resistance (DR and MDR), making the treatment of TB extremely difficult and even impossible and placing the disease among the major causes of death worldwide. There is strong evidence of the critical roles of *Mtb* membrane exporters functioning as anti-TB drug efflux pumps in DR and MDR TB, and strategies to inhibit the function of these proteins are necessary. However, the studies of *Mtb* drug exporters have progressed slowly and are insufficient. One reason is that these proteins are very difficult to produce recombinantly and to isolate in pure form. Here, we report our progress in studies of the *Mtb* EfpA efflux pump. This protein exports anti-TB drugs (including first- and second-lines anti-TB drugs) out of the *Mtb* cell, thus reducing the effect of treatments. We developed efficient protocols for the production of this protein in *E. coli* and its purification, which will be highly beneficial for further structural and functional studies to characterize in detail the molecular mechanisms of *Mtb* EfpA and might direct the studies on other *Mtb* drug exporters, as well. Our findings also suggest that *Mtb* EfpA forms homo-oligomers in detergent and lipid, which might reflect the protein's native functional state.

INTRODUCTION

Mycobacterium tuberculosis (*Mtb*) is the causative agent of tuberculosis (TB), one of the most devastating and hard-to-control infectious diseases, which leads to severe health complications and often death. Worrisomely, in the last years, the number of drug resistant TB (DR-TB) strains has increased significantly; annually, over half a million new cases of multidrug-resistant TB (MDR-TB) emerge, many of them either extensively or totally drug resistant, rendering them nontreatable with first- and second-line anti-TB antibiotics.[1,2] Mutations in the *Mtb*-drug-target genes have been considered a mainstream mechanism to develop DR-TB and MDR-TB.[3-5] In addition, strong evidence points to *Mtb* membrane exporters' critical roles in DR-TB and MDR-TB, and strategies to develop inhibitors of these proteins are in progress.[4,6-10] In regard to this, the membrane efflux system's important role in DR and MDR of other pathogenic bacteria is now well recognized, necessitating a comprehensive understanding of how these proteins function to inform on inhibitors' development.[11-16]

We focused on the *Mtb* drug exporter EfpA (efflux protein A).[17] EfpA belongs to the major facilitator superfamily (MFS) of transporters, and it expels drugs from the cell for the antiport of H^+. More narrowly, EfpA belongs to the subfamily of QacA transporters,[17] which are linked to drug resistance.[18] Researchers have confirmed EfpA's role in anti-TB drug export and DR/MDR in several studies: Substantially increased levels (up to 4 times) of EfpA expression in MDR-*Mtb* isolates[7] and genetically modified *Mtb* strains[19] upon isoniazid, rifampicin (first-line anti-TB drugs), and ethionamide (second-line anti-TB drug) treatment were detected. EfpA was linked to increased resistance to a combination of isoniazid and ethambutol.[20] It was found further that the overexpression of EfpA protein from *M. smegmatis*, which shares 80% identity with the *Mtb* EfpA, induces high drug tolerance (MDR) to several first- and second-line anti-TB drugs, including rifampicin (observed 4-fold increased resistance), isoniazid, streptomycin, amikacin (16-fold increase), and ethidium bromide.[21] Therefore, the role of *Mtb* EfpA in DR and MDR is evident. This protein is now recognized as a very specific *mycobacterial* druggable target, prompting the search for efficient EfpA inhibitors.[22] To this end, comprehensive studies to understand EfpA-anti-TB drug interactions and transport will be very informative. However, such studies have been very limited, possibly because of the unavailability of recombinantly expressed and purified EfpA.

Here, we report our efforts to overcome the deficiencies in the *in vitro* studies of *Mtb* EfpA by developing strategies to express this protein in *E. coli* and purify it sufficiently for further studies.

To do so, we utilized protein engineering to generate a chimera construct containing the apolipoprotein A-I (apoAI) fused to the N-terminal of EfpA (apoAI-EfpA construct), which enabled us to express the protein in an *E. coli* membrane-bound form. To the best of our knowledge, this is the first complete protocol for the heterologous expression and purification of *Mtb* EfpA reported. Interestingly, when the apoAI-EfpA was reconstituted in lipid membranes comprising DOPC (1,2-Dioleoyl-sn-glycero-3-phosphocholine) and DOPS (1,2-dioleoyl-sn-glycero-3-phospho-L-serine), we found by negative staining electron microscopy (nsEM) that it forms protein-lipid discoidal nanoparticles resembling nanodiscs, presumably due to the apoAI moiety.[23,24] To enhance our studies on *Mtb* EfpA, we used bioinformatic tools to predict EfpA membrane topology, confirming its 14-transmembtane helices' organization.[25] We also studied the degree of conservation of EfpA exporters among *mycobacterial* species and found a high degree of identity (greater than 85% among the studied species), but we found only about 20% identity between Mtb EfpA and homologues of the QacA subfamily. This finding again confirms these proteins' exclusive specificity to *mycobacteria*. Next, based on the available high-resolution structures of distant protein homologues, we generated structural models of this protein in its inward- and outward-facing states, suggesting conformational rearrangements upon substrate translocation.

RESULTS

The expressed in *E. coli* chimera construct apoAI-EfpA is a membrane-bound protein

In our initial attempts to produce in *E. coli* the full-length (FL) EfpA with just a polyhistidine (His$_8$) tag as well as with a combined His$_8$ and FLAG tag, we found that upon expression, the protein was deposited in the insoluble inclusion bodies, similar to other *Mtb* membrane proteins.[26] Therefore, the further purification of this protein required inclusion bodies' solubilization using high concentration of sodium dodecyl sulfate (SDS) and protein refolding by stepwise addition of milder detergent n-dodecyl-β-D-maltoside (β-DDM) while removing SDS (Supporting Information and Supporting Figure 1).

This requirement prompted us to look for alternative strategies to produce EfpA in a more native state. To do so, we engineered a chimera construct of apolipoprotein A-I (ApoAI), relying on previously developed protocols using apoAI fused to the C-terminus of several integral membrane

proteins to produce them in a soluble form.[27] However, we fused the apoAI to the N-terminus of EfpA (apoAI-EfpA construct) (Figure 1A and Supporting Figure 2). In the linker between apoAI and EfpA, we engineered two recognition sites for SUMO and Thrombin (Thr) proteases. This construct's total calculated molecular weight is 84.8 kDa. We cloned the gene encoding this chimera construct in the pET15b expression vector (Figure 1B). When it is expressed in *E. coli*, we expected to find the protein in the soluble cytoplasmic fraction, as in a previous study.[27] Surprisingly, when we screened all the cell fractions (i.e., cytoplasmic, membrane, and inclusion bodies), the membrane fraction contained most of the protein (Supporting Figure 2). Therefore, we proceeded with handling the apoAI-EfpA as a membrane protein.

Figure 1. Design and cloning of the apoAI-EfpA chimera construct. (A) A cartoon representation of the apoAI-EfpA construct: His8+apoAI tag (in gray and blue, respectively) was fused to the N-terminus of EfpA; the protease recognition sites between apoAI and EfpA are in orange; EfpA is in red. (B) The gene encoding the apoAI-EfpA was cloned in pET15b vector between the NcoI and BamHI restriction sites resulting in an apoAI-EfpA/pET15b protein expression vector. The vector map was created using the GenSmartTM (GenScript) software.

We solubilized the membranes by using high (30-35 mM) β-DDM and purified the apoAI-EfpA using Ni-affinity and Co-affinity chromatography sequentially. The isolated protein was of sufficient purity (Figure 2). In addition to the bands at the molecular weight of apoAI-EfpA, sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS-PAGE) and western blotting (WB) displayed His-tag–positive protein bands at molecular weight below that of the apoAI-EfpA monomer, possibly due to fractional protein degradation or anomalous migration of an effectively smaller protein due to its more folded state in SDS. The latter is plausible because we observed similarly low-molecular-weight protein bands for the ApoAI-free EfpA constructs purified from inclusion bodies (Supporting Figure 1).

Figure 2. SDS-PAGE and western blotting (WB) of the purified *Mtb* EfpA in detergent β-DDM and in lipid.

Negative staining electron microscopy suggests that apoAI-EfpA forms a homo-oligomer and assembles into nanodisc-like protein-lipid particles when reconstituted in lipid

We subjected the Co-affinity purified apoAI-EfpA in β-DDM to nsEM and obtained clear images of detergent-solubilized protein containing protein particles, which are apparently larger than expected for a protein of about 84 kDa (Figure 3A, Supporting Figure 3). This result prompted us to explore further the ability of this protein's ability to form oligomers. To gain insights into the oligomeric state of apoAI-EfpA, we labeled the N-terminus His-tag of the protein with 5 nM gold nanoparticles (GNPs). The nsEM images of this sample clearly show clusters of protein-associated

GNPs ranging from 1 to 4 (Figures 3B and C), suggesting that apoAI-EfpA is indeed oligomeric. Interestingly, we did not observe protein clusters with more than 4 GNPs, which might indicate that the tetramer is the highest-order oligomer of this protein in β-DDM. One consideration here is that the concentration of GNPs in the studied samples was significantly smaller than the protein concentration (18 µM protein/0.14 µM GNP). Therefore, it is reasonable to expect that most of the protein molecules do not have a GNP attached to them. If further consider statistical distribution of protein-bound GNPs within the apoAI-EfpA oligomers, observing oligomers with 1, 2, or 3 protomers having GNPs as well as protein oligomers having no GNPs is also expected.

apoAI-EfpA in β-DDM

Figure 3. nsEM images of apoAI-EfpA in β-DDM. (A) A selected image of a protein sample without GNPs; (B) and (C) Selected images of protein labeled with GNP-s (black dots); (D) An expanded view of the image region enclosed in the yellow rectangle in (C). The scale bar in all images is 100 nm. In all images, apoAI-EfpA oligomers are visible, particularly exemplified by the clusters of protein-bound GNP-s. The red numbers in (C) show the apparent number of GNP-s within a protein cluster. Note, the number of GNP-s does not report directly on the number of protein monomers, as the concentration of GNP-s in the imaged sample was about 130 times less than the concentration of protein. Still, the grates number of GNP-s observed is four, which might indicate that this is the highest order of the apoAI-EfpA oligomer.

We further reconstituted the apoAI-EfpA in a mixture of DOPC/DOPS lipids at a 70:30 molar ratio of noncharged to charged lipids. To ensure the protein incorporation in the lipid environment,

we first solubilized the lipid bilayers (multilamellar vesicles) with Triton-100 and then added to them the apoAI-EfpA in β-DDM. After incubating this mixture for 1 h at 22 °C, we gradually removed the detergents.[28,29]

apoAI-EfpA in DOPC/DOPS

Figure 4. nsEM images of apoAI-EfpA in lipid. (A) and (B) Selected images for protein with no GNPs; (C) and (D) Selected images for protein labeled with GNPs (black dots); (E) An expanded view of the image region enclosed in the yellow rectangle in (D). The scale bar is 100 nm. All images show that upon reconstitution in DOPC/DOPS lipids, apoAI-EfpA formed nano-sized (about 10 – 20 nm in diameter) protein-lipid particles. Again, protein oligomers with order of up to four (based on the number of clustered NGPs) was observed.

Using nsEM, we again visualized the proteolipid samples with and without GNP-s attached to the protein. In this case, we observed discoidal protein-lipid nanoparticles with a diameter of about average 20 nm (Figure 4 and Supporting Figure 3). These structures resemble proteins incorporated in nanodiscs, which are also lipid nanoparticles stabilized by a belt of a scaffold

proteins (apolipoprotein AI).[30-32] Therefore, because our chimera construct contains apoAI, it is not surprising that nanodisc-like particles were formed. Still, in the conventional case, 2 copies of the scaffold proteins are necessary to stabilize a single nanodisc,[30] but for the apoAI-EfpA, we observed up to 4 protein-bound GNP-s in a single discoidal structure (Figures 4C, D, and E), suggesting a tetrameric protein. Similar to protein in β-DDM, under our experimental conditions, the GNPs concentration was substantially lower than the protein concentration. Therefore, not all apoAI-EfpA monomers have a GNP attached to them. Besides confirming the oligomeric structure of EfpA, this observation might suggest that the EfpA forms a sufficiently tight oligomer, which is able to restructure the nanodiscs to include up to 4 copies of apoAI. If this is the case, our results might indicate that nanodiscs could possess adequate structural and size flexibility to accommodate membrane proteins of various sizes. Further studies will provide more detail on this matter. Another important aspect of this observation is that we were successful in creating a chimera protein that carries the transmembrane protein and the scaffold protein, which can form proteolipid nanoparticles on its own. The designed protease sites (i.e., SUMO and Thr) could provide even more flexibility in the system by separating the apoAI tag from EfpA, which will be explored in future studies.

Another striking observation in our study is the oligomerization of EfpA in detergent and lipid. This protein is one of the MFS transporters,[6,17] which are typically monomeric proteins, and oligomerization is generally not necessary for substrate translocation.[33,34] Still, oligomerization of MFS membrane transporters was observed previously (e.g., the human proton-coupled folate transporter[35] and the plant nitrate transporter, NRT1.1).[36] The oligomerization of *Mtb* EfpA might play a stabilizing or regulatory role, which could be determined in subsequent studies.

Bioinformatic analysis confirms that *Mtb* EfpA is a 14-transmembrane-helix explicitly *mycobacterial* MFS transporter

To expand our studies and supplement our experimental data, we conducted a bioinformatic analysis of the *Mtb* EfpA protein.

Figure 5. The *Mtb*-encoded EfpA efflux pump. (**A**) Amino acid sequence and (**B**) Predicted protein topology—TMs are numbered from 1 to 14 in blue; N- and C-termini have intracellular (cytoplasmic) location.

The EfpA exporter has a 14-transmembrane-helix topology: To assess the topology of the membrane-residing *Mtb* EfpA exporter, we utilized the *Protter* proteoform visualization program,[37] which predicted 14-transmebrane helices (TMs) with intracellular location of the N- and C-termini (Figure 5). This supports the previous prediction regarding EfpA,[17] and the location of termini coincides with those of other MSFs with 14- and 12-TMs.[34,38,39]

The amino acid sequence of EfpA exporters is highly conserved among mycobacterial species but shares low similarity with the QacA family: Because EfpA is a member of the QacA family,[17] but is mostly limited to *mycobacteria*,[8,17] we aimed to determine the degree of identity between *Mtb* EfpA with homologues from other *mycobacterial* species and among QacA exporters. Based on

the amino acid sequences' alignment, we found that the EfpA efflux pumps encoded by several selected *mycobacterial* species are highly conserved: Among all the *mycobacterial* species we studied, the identity of EfpA proteins is greater than 85%. This result agrees with the literature.[17] This amino acid sequences' alignment included EfpAs from *M. tuberculosis*, *M. shinjukuense* (causes pulmonary infection[40]), *M. simiae* (infection leads to bronchiectasis, micronodular lesions, and weight loss[41]), *M. szulgai* (also causes lung diseases[42]), *M. arosiense*, and *M. intracellulare* (Figure 6). On the other hand, our analysis of the amino acid sequences of selected QacA family proteins (QacA of *S. Aureus*, EmrB/QacA of *B. Pseudomallei*, EmrB/QacA of *C. Disporicum*, etc.) (Figure 7) revealed relatively low identity, ca. 20%, of *Mtb* EfpA with the rest of the studied proteins. These results, together with the limited occurrence of EfpA in bacterial genomes, emphasize this protein's exclusiveness to *mycobacteria* and might suggest unique details in its mechanism.

Figure 6. **The amino acid sequence alignment of EfpA proteins encoded by selected** *mycobacterial* **species**, which are *M. tuberculosis*, *M. shinjukuense*, *M. simiae*, *M. szulgai*, *M. arosiense*, and *M. intracellulare*. The T-COFFEE Multiple Sequence Alignment software was used to perform the analysis and visualize the data. The amino acids are colored by identities.

Figure 7. Amino acid sequence alignment of selected members of the QacA family of exporters, which are *Mtb* EfpA, QacA *S. Aureus*, EmrB/QacA *B. Pseudomallei*, EmrB/QacA *C. Disporicum*, FarB *N. Gonorrhoeae*, TCMA_STRGA *S. Glaucescens*. The T-COFFEE Multiple Sequence Alignment software was used to perform the analysis and visualize the data. The amino acids are colored by identities.

Structural models of Mtb EfpA in outward- and inward-facing conformations reveal possible structural rearrangements: We used the SWISS-MODEL program[43] to generate the 3D structural models of *Mtb* EfpA (Figure 8). We used the existing X-ray structures of the *S. aureus* NorC (PDB#7D5Q) and *E. coli* DtpA (PDB#6GS1) in outward- and inward-facing conformation as templates.[38,39] The models revealed large conformational changes upon transition from outward- to inward-facing states underlying the binding and translocation of substrate(drug)/H$^+$. These conformational isomerizations are in agreement with the "rocking-switch" mechanism of the MSF transporters.[33,34] The generated model conformations would be useful in further characterization of the *Mtb* EfpA structure–function relationship. However, experimental and detailed computational data would also be needed to elucidate the specificity in the functional mechanism of the *Mtb* EfpA because this protein shares less than 20% and 30% identity with NorC and DtpA, respectively, as our analyses revealed; it is also very specific for *mycobacteria*, as mentioned above.

Inward-facing conformation   **Outward-facing conformation**

Figure 8. Structural models of *Mtb* EfpA in inward and outward facing conformations based on the X-ray structures of NorC (PDB#7D5Q) and DtpA (PDB#6GS1). The TMs undergoing large conformational isomerization upon transition from inward to outward facing conformation based on these models are colored as follows: residues 89-115 are in pink, residues 141-169 are in light-blue, residues 174-202 are in yellow, residues 397-426 are in ruby. Membrane is in yellow-orange.

DISCUSSION

Understanding the structure, conformational dynamics, drug specificity, and drug translocation mechanism of *Mtb* drug exporters is important for the development of informed strategies to inhibit these proteins. To date, most of these proteins have not been produced in purified form, hindering the *in vitro* investigations. Here, we focus on the *Mtb* EfpA drug exporter. Several drug substrates of EfpA, including first- and second-line anti-TB drugs, were proposed, and the literature provides solid evidence of this protein's role in DR and MDR development.[7,19-21] However, currently, molecular details about the mechanism(s) of EfpA are very limited; no studies to produce and isolate this protein have been published except our recent short report.[44] In the current study, we made significant progress by developing strategies to produce this protein in an *E. coli* host recombinantly and purify it to relatively high degree. To do so, we engineered a chimera construct apoAI-EfpA that had plasma membrane localization when expressed in *E. coli*, which enabled us to handle apoAI-EfpA as a membrane protein (i.e., to extract it from the membrane using detergent, purify it in detergent, and then reconstitute it in lipid membranes). To the best of our knowledge, this is the first protocol reported for the expression and purification of the FL *Mtb* EfpA drug exporter. Such an achievement could be an important stepping stone in the in vitro investigations of EfpA because it will open up future opportunities to elucidate the structure–function relationship of this protein. In addition, the apoAI-EfpA construct has the advantage of forming protein-lipid discoidal nanoparticles, similar to the nanodiscs used in membrane protein studies.[23,24,45] This could make it possible to characterize EfpA's properties in a system comprising just 2 components, the apoAI-EfpA and lipid. The methodology could be further explored in studies of other membrane proteins. Interestingly, we detected EfpA oligomerization in β-DDM and DOPC/DOPS lipids, with tetramer being the largest oligomer visualized by nsEM. This finding might suggest that the *Mtb* EfpA functions as an oligomeric protein, but further details would be necessary. All the developments reported here could promote further comprehensive studies of the *Mtb* EfpA protein's molecular mechanisms.

MATERIALS AND METHODS

Cloning, expression, and purification of *Mtb* EfpA as a fusion construct with apoAI

Three fusion constructs of *Mtb* EfpA were designed: His$_8$-linker-*Mtb* EfpA, His$_8$-linker-FLAG-linker-*Mtb* EfpA, and His$_8$-linker-apolipoprotein A-I (apoAI)-linker-SUMO protease site-linker-Thrombin protease site-linker-*Mtb* EfpA. The DNA encoding each of these constructs was commercially synthesized and cloned in pET15b vector at NcoI and BamHI sites (*GenScript*, Inc) and then transformed into Bl21(DE3) *E. coli* cells. However, upon expression in *E. coli*, we found that the first 2 fusion proteins were deposited in the insoluble inclusion bodies[46] (Supporting Information). Therefore, we proceeded with the third construct, in which apoAI was fused to the N-terminus of *Mtb* EfpA. Throughout the text in this paper, we refer this construct as apoAI-EfpA. After transforming the plasmid DNA encoding apoAI-EfpA into *E. coli* BL21(DE3) chemically competent cells, colonies were grown on LB/agar/100 µg/ml Ampicillin (Amp) plates overnight at 37 °C. The next day, 200 mL of LB medium supplemented with 100-µg/ml Amp were inoculated with a single colony of transformed cells, and an overnight culture was grown at 37 °C in a shaker incubator. The next day, 30 mL of this overnight culture was transferred into large flasks containing 2 L LB medium supplemented with 100-µg/ml Amp. The cells were further grown at 37 °C in a shaker incubator until the cell culture OD reached 0.6-0.8; then, the temperature was decreased to 14 °C, and the protein expression under the control of the T7 promoter was initiated by adding 0.5 mM IPTG (Isopropyl ß-D-1-thiogalactopyranoside) to the cell culture. The expression proceeded overnight at 14 °C for about 16 h.

The next day, the cells were harvested by centrifugation at 4,100 rpm in an Avanti J-15R centrifuge (Backman Coulter) and resuspended in a buffer containing 20 mM HEPES pH 7.4, 300 mM NaCl and 5% glycerol (Buffer A). All following procedures were carried out either on ice or at 4 °C. PMSF (phenylmethylsulfonyl fluoride), lysozyme, and TCEP (tris(2-carboxyethyl)phosphine) were added to the cell solution to 1-mM, 0.6-mg/ml, and 200-µM final concentrations, respectively. The cells were broken open by sonication. The unbroken cells, cell debris, and inclusion bodies were spun down in an Avanti J-15R (Beckman Coulter) centrifuge at 5,500 rpm for 15 min at 4 °C, and the cell membranes were spun down in an Optima XE-90 ultracentrifuge (Beckman Coulter) in a rotor type 70.1Ti at 40,000 rpm (146,550.4xg) for 1 h at 4 °C. All fractions (i.e., cell debris with inclusion bodies, membranes, and soluble) were subjected to SDS-PAGE and

WB to determine the location of the expressed apoAI-EfpA. In several repeated experiments, we found the protein only in the membrane fraction because the soluble and insoluble fractions were WB-negative for this protein.

Afterward, we followed the procedure for membrane solubilization and protein extraction in detergent n-Dodecyl-beta-Maltoside (β-DDM), as previously described.[28] The detergent-solubilized apoAI-EfpA was purified using Ni-affinity and Co-affinity chromatography techniques sequentially. Briefly, the protein mixture was incubated with Ni-NTA resin (*Quagene*) for 1 h at 4 °C, the fraction of unbound protein was discarded, and the Ni-NTA resin with bound apoAI- EfpA was washed with 12 resin volumes of Buffer A supplemented with 1 mM β-DDM, 200 µM TCEP, 100 µM PMSF, and 50 mM Imidazole. The protein was eluted with 2.5 resin volumes of the same buffer but containing 300 mM instead of 50 mM Imidazole. Then, the buffer was exchanged in 50-kDa MWCO centrifuge concentrators to 20 mM Tris/HCl pH 7.4, 150 mM NaCl, 100 µM TCEP, 1 mM β-DDM (Buffer B), and 15 mM Imidazole, and the protein solution was mixed with Co resin (His-select Cobalt Affinity Gel, *Sigma Aldrich*) for 1h at 4 °C. The unbound fraction was discarded, and the resin was washed with 3 volumes of Buffer B containing 20 mM Imidazole. The apoAI-EfpA protein was eluted with Buffer B containing 300 mM Imidazole. Then, Imidazole was removed from the protein solution by extensive washing with Buffer B in 50-kDa MWCO centrifuge concentrators. The Imidazole-free solution was concentrated to ca. 25- 50 µM apoAI-EfpA, frozen, and stored at -80 °C.

Sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS-PAGE) and western blotting (WB) to detect the expression and purity of apoAI-EfpA

All *E. coli* cell fractions (insoluble fraction with inclusion bodies, membranes, and soluble fractions) were tested for the expression and localization of apoAI-EfpA using SDS-PAGE and WB. The purity of apoAI-EfpA after Ni-affinity and Co-affinity chromatography was assessed using SDS-PAGE and WB. All the samples for SDS-PAGE and WB constituted protein, DTT (dithiothreitol) at 10 mM, and a loading buffer. The samples and marker (Precision plus protein dual-color standard, *BioRad*) were loaded onto 4%-20% Criterion™ TGX™ precast gels (*BioRad*) immersed in Tris/glycine/SDS buffer (*BioRad*), and then electrophoresis was conducted in a Midi Criterion™ vertical electrophoresis cell (*BioRad*) at 170 V. For blotting, the protein was transferred from the gel onto a 0.2-µm nitrocellulose membrane (*BioRad*) using a Criterion™

blotter (*BioRad*) overnight at 10 V and 4 °C. Protein bands on the gel were visualized by Coomassie Blue dye staining and washing with de-stain solution. We utilized colorimetric detection to visualize the MBP-Vpu band(s) on the membrane after WB transfer: The primary mouse antihistidine tag antibody (*BioRad*) and secondary goat antimouse IgG antibody conjugated to Alkaline Phosphatase (*BioRad*) were used.

Lipid preparation of lipid stock solution and reconstitution of apoAI-EfpA in lipid nanoparticles

DOPC (1,2-dioleoyl-sn-glycero-3-phosphocholine; 18:1 [Δ9-Cis] PC) and DOPS (1,2-dioleoyl-sn-glycero-3-phospho-L-serine) lipids (purchased from *Avanti Polar Lipids*) in chloroform or chloroform/methanol/water were mixed in a glass vial at molar ratio of 70:30, and the solvent was evaporated under a stream of nitrogen gas. The vial was flashed until the liquid was visibly evaporated and then flashed for at least 2 h more to remove the residual organic solvent. Then a buffer containing 20 mM Tris/HCl pH 7.4 and 150 mM NaCl was added in the vial to the dry lipid film to obtain a final total lipid concentration of 30 mM. The lipid/buffer mixture was incubated for 30 min on ice to ensure complete lipid hydration. This stock solution was then used to reconstitute the apoAI-EfpA protein in lipid bilayers.

Thereafter, an aliquot of lipid stock solution was placed in a 1.5-ml tube, and the lipid was solubilized using 10% of Triton X-100 detergent in H_2O. Then, the necessary volumes of apoAI-EfpA in β-DDM and buffer (20 mM Tris/HCl pH 7.4 and 150 mM NaCl) were added to the lipid solution to obtain a final protein-to-lipid molar ratio of 1:120, lipid concentration of 1.8 mM, and protein concentration of 15 µM. The mixture was incubated for 1h at 22 °C. Then, BioBeads (*BioRad*) were added, and the mixture was incubated under constant mixing for 2 h at 22 °C. The BioBeads were changed 2 more times after incubation for 2 h and then overnight at 4 °C to remove the detergents completely. This proteolipid sample was used for negative staining transmission electron microscopy (nsEM) assessments.

Preparation of samples for nsEM and nsEM imaging of the apoAI-EfpA protein

Prior to the negative staining, aliquots of the apoAI-EfpA in β-DDM and in lipid were placed in 1.5-ml tubes and then mixed with 5-nm Gold Nanoparticles (5-nm Gold-Ni-NTA, *Nanoprobes*) (GNPs) for 30-40 min at 4 °C. These GNPs bind to the protein His-tag.[47] The protein-to-GNPs

molar ratios were ca. 1:130 and 1:100 for protein in detergent and in lipid, respectively. We prepared and used 5 samples for nsEM: GNPs-labeled protein in β-DDM (18 μM protein), nonlabeled protein in β-DDM (18 μM protein), GNPs-labeled protein in lipid (11.25 μM protein), nonlabeled protein in lipid (11.25 μM protein), and nonlabeled protein in lipid (15 μM protein). A 15-μl sample was loaded onto a carbon-coated copper grid and allowed to settle for 1min30sec at room temperature. Then, the solution on the grid was removed gently using filter paper, and the settled on the grid protein in detergent or lipid was stained by adding 10 μL of 1.5% uranyl acetate (UA), incubated for 1min30sec, and the remaining UA solution was again cleared gently using filter paper. Stained samples were air dried overnight and then used for EM imaging.

The digital micrographs of negatively stained samples were collected using a transmission electron microscope (TEM *Hitachi H-7650*) equipped with a fluorescent screen with a visual field diameter of 160 mm and operated at an accelerating voltage of 60 kV with a 10-μA emission current. The direct magnification used was ×40,000-70,000. Micrographs devoid of drift and astigmatism were scanned at 1,024×1,024 pixels.

Bioinformatic analysis of *Mtb* EfpA

The *Protter - visualize proteoform*[37] was used to predict and visualize the *Mtb* EfpA topology in the membrane bilayer. The NCBI BLAST algorithm and the T-COFFEE Multiple Sequence Alignment software were used to predict the identities and align the amino acid sequences between EfpA exporters from various *mycobacterial* species as well as between *Mtb* EfpA and other QacA subfamily trasporters. Next, the SWISS-MODEL software[48] was used to generate models of *Mtb* EfpA in outward- and inward-facing conformations, which were based on homology with existing X-ray structures of NorC (PDB#7D5Q) and DtpA (PDB#6GS1).[38, 39]

AUTHOR CONTRIBUTION

OI – experiment, figures, data analysis; AO – experiment, figures; MMI – experiment; EH – experiment, SM – experiment, figures; OA – experiment; ERG – conception, design, experiment, data analysis and interpretation, drafting the manuscript, funds acquisition, supervision. All authors contributed to the finalization of the manuscript. All authors read and approved the final version of the manuscript.

ACKNOWLEDGMENTS

nsEM was conducted at the Art&Sciences Imaging Facility, TTU. This study was supported by a Royal Society of Chemistry Research Grant R22-2811992318 (to ERG) and start-up funds from the Department of Chemistry and Biochemistry at TTU (to ERG)

REFERENCES

1. Dall C. 2017. Report warns of rise on drug-resistant tuberculosis. Accessed

2. Mase SR, Chorba T. 2019. Treatment of Drug-Resistant Tuberculosis. Clin Chest Med 40:775-795.

3. Ghajavand H, Kargarpour Kamakoli M, Khanipour S, Pourazar Dizaji S, Masoumi M, Rahimi Jamnani F, Fateh A, Yaseri M, Siadat SD, Vaziri F. 2019. Scrutinizing the drug resistance mechanism of multi- and extensively-drug resistant Mycobacterium tuberculosis: mutations versus efflux pumps. Antimicrob Resist Infect Control 8:70.

4. Gygli SM, Borrell S, Trauner A, Gagneux S. 2017. Antimicrobial resistance in Mycobacterium tuberculosis: mechanistic and evolutionary perspectives. FEMS Microbiol Rev 41:354-373.

5. Morlock GP, Metchock B, Sikes D, Crawford JT, Cooksey RC. 2003. ethA, inhA, and katG loci of ethionamide-resistant clinical Mycobacterium tuberculosis isolates. Antimicrob Agents Chemother 47:3799-805.

6. Szumowski JD, Adams KN, Edelstein PH, Ramakrishnan L. 2013. Antimicrobial efflux pumps and Mycobacterium tuberculosis drug tolerance: evolutionary considerations. Curr Top Microbiol Immunol 374:81-108.

7. Li G, Zhang J, Guo Q, Jiang Y, Wei J, Zhao LL, Zhao X, Lu J, Wan K. 2015. Efflux pump gene expression in multidrug-resistant Mycobacterium tuberculosis clinical isolates. PLoS One 10:e0119013.

8. da Silva PE, Von Groll A, Martin A, Palomino JC. 2011. Efflux as a mechanism for drug resistance in Mycobacterium tuberculosis. FEMS Immunol Med Microbiol 63:1-9.

9. Machado D, Perdigao J, Portugal I, Pieroni M, Silva PA, Couto I, Viveiros M. 2018. Efflux Activity Differentially Modulates the Levels of Isoniazid and Rifampicin Resistance among Multidrug Resistant and Monoresistant Mycobacterium tuberculosis Strains. Antibiotics (Basel) 7.

10. Louw GE, Warren RM, Gey van Pittius NC, McEvoy CR, Van Helden PD, Victor TC. 2009. A balancing act: efflux/influx in mycobacterial drug resistance. Antimicrob Agents Chemother 53:3181-9.

11. Soto SM. 2013. Role of efflux pumps in the antibiotic resistance of bacteria embedded in a biofilm. Virulence 4:223-9.

12. Wang-Kan X, Blair JMA, Chirullo B, Betts J, La Ragione RM, Ivens A, Ricci V, Opperman TJ, Piddock LJV. 2017. Lack of AcrB Efflux Function Confers Loss of Virulence on Salmonella enterica Serovar Typhimurium. mBio 8.

13. Marshall RL, Lloyd GS, Lawler AJ, Element SJ, Kaur J, Ciusa ML, Ricci V, Tschumi A, Kuhne H, Alderwick LJ, Piddock LJV. 2020. New Multidrug Efflux Inhibitors for Gram-Negative Bacteria. mBio 11.

14. Grimsey EM, Weston N, Ricci V, Stone JW, Piddock LJV. 2020. Overexpression of RamA, Which Regulates Production of the Multidrug Resistance Efflux Pump AcrAB-TolC, Increases Mutation Rate and Influences Drug Resistance Phenotype. Antimicrob Agents Chemother 64.

15. Du D, Wang-Kan X, Neuberger A, van Veen HW, Pos KM, Piddock LJV, Luisi BF. 2018. Multidrug efflux pumps: structure, function and regulation. Nat Rev Microbiol 16:523-539.

16. Lomovskaya O, Watkins WJ. 2001. Efflux pumps: their role in antibacterial drug discovery. Curr Med Chem 8:1699-711.

17. Doran JL, Pang Y, Mdluli KE, Moran AJ, Victor TC, Stokes RW, Mahenthiralingam E, Kreiswirth BN, Butt JL, Baron GS, Treit JD, Kerr VJ, Van Helden PD, Roberts MC, Nano FE. 1997. Mycobacterium tuberculosis efpA encodes an efflux protein of the QacA transporter family. Clin Diagn Lab Immunol 4:23-32.

18. Marger MD, Saier MH, Jr. 1993. A major superfamily of transmembrane facilitators that catalyse uniport, symport and antiport. Trends Biochem Sci 18:13-20.

19. Wilson M, DeRisi J, Kristensen HH, Imboden P, Rane S, Brown PO, Schoolnik GK. 1999. Exploring drug-induced alterations in gene expression in Mycobacterium tuberculosis by microarray hybridization. Proc Natl Acad Sci U S A 96:12833-8.

20. Gupta AK, Katoch VM, Chauhan DS, Sharma R, Singh M, Venkatesan K, Sharma VD. 2010. Microarray analysis of efflux pump genes in multidrug-resistant Mycobacterium tuberculosis during stress induced by common anti-tuberculous drugs. Microb Drug Resist 16:21-8.

21. Rai D, Mehra S. 2021. The Mycobacterial Efflux Pump EfpA Can Induce High Drug Tolerance to Many Antituberculosis Drugs, Including Moxifloxacin, in Mycobacterium smegmatis. Antimicrob Agents Chemother 65:e0026221.

22. Johnson EO, Office E, Kawate T, Orzechowski M, Hung DT. 2019. Discovery of a novel synergistic antimycobacterial combination targeting EfpA using large-scale chemical-genetics doi:https://doi.org/10.1101/772459. bioRxiv, https://www.biorxiv.org/content/10.1101/772459v1.full.pdf.

23. Denisov IG, Sligar SG. 2016. Nanodiscs for structural and functional studies of membrane proteins. Nat Struct Mol Biol 23:481-6.

24. Denisov IG, Sligar SG. 2017. Nanodiscs in Membrane Biochemistry and Biophysics. Chem Rev 117:4669-4713.

25. Remm S, Earp JC, Dick T, Dartois V, Seeger MA. 2022. Critical discussion on drug efflux in Mycobacterium tuberculosis. FEMS Microbiol Rev 46.

26. Korepanova A, Moore JD, Nguyen HB, Hua Y, Cross TA, Gao F. 2007. Expression of membrane proteins from Mycobacterium tuberculosis in Escherichia coli as fusions with maltose binding protein. Protein Expr Purif 53:24-30.

27. Mizrachi D, Chen Y, Liu J, Peng HM, Ke A, Pollack L, Turner RJ, Auchus RJ, DeLisa MP. 2015. Making water-soluble integral membrane proteins in vivo using an amphipathic protein fusion strategy. Nat Commun 6:6826.

28. Georgieva ER, Borbat PP, Ginter C, Freed JH, Boudker O. 2013. Conformational ensemble of the sodium-coupled aspartate transporter. Nat Struct Mol Biol 20:215-21.

29. Georgieva ER, Borbat PP, Norman HD, Freed JH. 2015. Mechanism of influenza A M2 transmembrane domain assembly in lipid membranes. Sci Rep 5:11757.

30. Bayburt TH, Sligar SG. 2002. Single-molecule height measurements on microsomal cytochrome P450 in nanometer-scale phospholipid bilayer disks. Proc Natl Acad Sci U S A 99:6725-30.

31. Denisov IG, Grinkova YV, Lazarides AA, Sligar SG. 2004. Directed self-assembly of monodisperse phospholipid bilayer Nanodiscs with controlled size. J Am Chem Soc 126:3477-87.

32. Majeed S, Ahmad AB, Sehar U, Georgieva ER. 2021. Lipid Membrane Mimetics in Functional and Structural Studies of Integral Membrane Proteins. Membranes (Basel) 11.

33. Yan N. 2015. Structural Biology of the Major Facilitator Superfamily Transporters. Annu Rev Biophys 44:257-83.

34. Drew D, North RA, Nagarathinam K, Tanabe M. 2021. Structures and General Transport Mechanisms by the Major Facilitator Superfamily (MFS). Chem Rev 121:5289-5335.

35. Hou Z, Kugel Desmoulin S, Etnyre E, Olive M, Hsiung B, Cherian C, Wloszczynski PA, Moin K, Matherly LH. 2012. Identification and functional impact of homo-oligomers of the human proton-coupled folate transporter. J Biol Chem 287:4982-95.

36. Fontenot EB, Ditusa SF, Kato N, Olivier DM, Dale R, Lin WY, Chiou TJ, Macnaughtan MA, Smith AP. 2015. Increased phosphate transport of Arabidopsis thaliana Pht1;1 by site-directed mutagenesis of tyrosine 312 may be attributed to the disruption of homomeric interactions. Plant Cell Environ 38:2012-22.

37. Omasits U, Ahrens CH, Müller S, Wollscheid B. 2014. Protter: interactive protein feature visualization and integration with experimental proteomic data. Bioinformatics 30:884-886.

38. Kumar S, Athreya A, Gulati A, Nair RM, Mahendran I, Ranjan R, Penmatsa A. 2021. Structural basis of inhibition of a transporter from Staphylococcus aureus, NorC, through a single-domain camelid antibody. Commun Biol 4:836.

39. Ural-Blimke Y, Flayhan A, Strauss J, Rantos V, Bartels K, Nielsen R, Pardon E, Steyaert J, Kosinski J, Quistgaard EM, Low C. 2019. Structure of Prototypic Peptide Transporter DtpA from E. coli in Complex with Valganciclovir Provides Insights into Drug Binding of Human PepT1. J Am Chem Soc 141:2404-2412.

40. Oshima K, Yokouchi H, Minemura H, Saito J, Tanino Y, Munakata M. 2015. Pulmonary Infection Caused by Mycobacterium shinjukuense. Ann Am Thorac Soc 12:958-9.

41. Coolen-Allou N, Touron T, Belmonte O, Gazaille V, Andre M, Allyn J, Picot S, Payet A, Veziris N. 2018. Clinical, Radiological, and Microbiological Characteristics of Mycobacterium simiae Infection in 97 Patients. Antimicrob Agents Chemother 62.

42. Maloney JM, Gregg CR, Stephens DS, Manian FA, Rimland D. 1987. Infections caused by Mycobacterium szulgai in humans. Rev Infect Dis 9:1120-6.

43. Guex N, Peitsch MC, Schwede T. 2009. Automated comparative protein structure modeling with SWISS-MODEL and Swiss-PdbViewer: a historical perspective. Electrophoresis 30 Suppl 1:S162-73.

44. Elka R. Georgieva, Akram B. Ahmad, Oluwatosin Adetuyi, Majeed S. 2022. Production of recombinant Mtb membrane efflux pump for structural and functional studies to reveal mechanisms of drug resistance. The FASEB Journal 36.

45. Henrich E, Peetz O, Hein C, Laguerre A, Hoffmann B, Hoffmann J, Dotsch V, Bernhard F, Morgner N. 2017. Analyzing native membrane protein assembly in nanodiscs by combined non-covalent mass spectrometry and synthetic biology. Elife 6.

46. Georgieva ER, Ahmad AB, Adetuyi O, Majeed S. 2022. Production of recombinant Mtb membrane efflux pump for structural and functional studies to reveal mechanisms of drug resistance. The FASEB Journal 36.

47. Majeed S, Adetuyi O, Borbat PP, Majharul Islam M, Ishola O, Zhao B, Georgieva ER. 2023. Insights into the oligomeric structure of the HIV-1 Vpu protein. J Struct Biol 215:107943.

48. Waterhouse A, Bertoni M, Bienert S, Studer G, Tauriello G, Gumienny R, Heer FT, de Beer TAP, Rempfer C, Bordoli L, Lepore R, Schwede T. 2018. SWISS-MODEL: homology modelling of protein structures and complexes. Nucleic Acids Res 46:W296-W303.